Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Congress Scientific Watch

The Congress Scientific Watch provides ESMO Members with fresh comments and analysis from selected abstracts presented during major international Oncology meetings.

Login to start reading, or Join ESMO - All articles are Open Access after 6 months.

Filter by:

58 results

Targeted Therapy;  Endocrine Therapy;  Prostate Cancer

TRITON3: PFS Boost With Rucaparib For BRCA-Positive Metastatic CRPC

From 2023 ASCO GU Cancers Symposium:
The use of rucaparib alongside a second-generation androgen receptor pathway inhibitor improves the outcome of patients with metastatic castration-resistant prostate cancer 

Targeted Therapy;  Endocrine Therapy;  Prostate Cancer

TALAPRO-2 First-Line Regimen Supported For Metastatic CRPC All-Comers

From 2023 ASCO GU Cancers Symposium:
Talazoparib plus enzalutamide has significantly extended radiographical progression-free survival for men with treatment-naïve metastatic castration-resistant prostate cancer 

Radiation Oncology;  Targeted Therapy;  Hepatobiliary Cancers

SBRT Boosts Overall Survival For Sorafenib-Treated Locally Advanced HCC Patients

From 2023 ASCO GI Cancers Symposium:
Adding stereotactic body radiation therapy to sorafenib significantly improves survival outcomes for patients with locally advanced hepatocellular carcinoma unsuitable for surgery, ablation or transarterial embolisation

Targeted Therapy;  Gastric Cancer

INTEGRATE IIa Supports Regorafenib For Advanced Gastro-Oesophageal Cancer

From 2023 ASCO GI Cancers Symposium:
Phase III trial findings point to a significant overall survival improvement with regorafenib versus placebo for treatment-refractory locally advanced or metastatic gastric or oesophagogastric junction cancer

Congress Watch archives 2022

The Congress Scientific Watch provides ESMO Members with comments and analysis from selected abstracts presented during major international Oncology meetings.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.